Open Orphan #ORPH – Investor presentations to provide introduction to new CEO Yamin ‘Mo’ Khan

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces it will provide two live investor presentations in March 2022. The presentations will provide investors with an introduction to new Chief Executive Officer, Yamin ‘Mo’ Khan, who will make his maiden presentations on Company progress.

London South East

Executive Chairman, Cathal Friel, and Chief Executive Officer, Yamin ‘Mo’ Khan, will give a live investor presentation via London South East alongside other companies as part of an investor webinar on Tuesday 8 March at 7.30 pm (GMT). The presentation is free to attend and requires investors to register via the London South East website. This can be accessed with the following link:

https://us02web.zoom.us/webinar/register/3816460478728/WN_kyeX1ibCT0aXEUdkO9gIOg

Investor Meet Company

Executive Chairman, Cathal Friel, and Chief Executive Officer, Yamin ‘Mo’ Khan, will host a second investor presentation via Investor Meet Company (“IMC”) on Tuesday 15 March at 6.00 pm (GMT). Investors can sign up to Investor Meet Company for free and request to meet Open Orphan plc via the following link:

https://www.investormeetcompany.com/open-orphan-plc/register-investor

Investors who already follow Open Orphan plc on the Investor Meet Company platform will automatically be invited.

Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of regulations and information already disclosed to the market through regulatory notifications. A recording of the presentation will be available on the Investor Meet Company platform afterwards. No new price sensitive information will be disclosed, and a PDF of the presentation will be uploaded to the Company’s website.

For further information please contact:

Notes to Editors

Open Orphan plc

Open Orphan plc (London and Euronext: ORPH) is a rapidly growing contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The Company provides services to Big Pharma, biotech, and government/public health organisations.

Open Orphan runs challenge studies in London from both its 19-bedroom Whitechapel quarantine clinic and its state-of-the-art 24-bedroom QMB clinic with its highly specialised on-site virology and immunology laboratory. The Company has a leading portfolio of human challenge study models for infectious and respiratory diseases and is developing a number of new models. There has been significant growth of the infectious disease market, which is estimated to grow to in excess of $250bn by 2025. The Group is focused on refreshing its existing challenge models and develop new models, such as Malaria, to address the dramatic growth potential of the global infectious disease market.

Building upon its many years of challenge studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company’s Disease in Motion® platform, this unique dataset includes clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has many potential applications across a wide variety of end users including big technology, wearables, pharma, and biotech companies.

Open Orphan’s Paris office has been providing biometry, data management and statistics to its many European pharmaceutical clients for over 20 years. For over 15 years, the Company’s Netherlands office has been providing drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), PK and medical writing, to a broad range of European clients. Both offices are now also fully integrated with the London office and working on challenge study contracts as well as supporting third party trial contracts.